Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines
By Karen Roman
Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.
The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.
“The recommendations for both olverembatinib and lisaftoclax (APG-2575) in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”
Contact:
Editor@executives-edge.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10